

Amendments to the Specification:

The following amendments refer to the paragraph numbering in the published application, US 2007/0224658 A1.

Please amend the specification at paragraph [0036] as follows:

[0036] In a preferment, the amino acid sequence can comprise either or both of the Apo B binding site sequence(s) depicted below in the same peptide or in the form of dimers or in different peptides:

(1) Lys Ala Glu Tyr Lys Lys Asn Lys His Arg His (SEQ ID NO:1);
or

(2) Arg Leu Thr Arg Lys Arg Gly Leu Lys (SEQ ID NO:2);

and analogues thereof which are capable of binding to the Apo B100 receptor site.

Please amend Table 1 of the specification, located immediately following paragraph [0061], as follows:

TABLE 1

Peptide	N-terminal	Sequence	C-terminal
1	Retinoic Acid	Leu-Arg-Leu-Thr-Arg-Lys-Arg-Gly-Leu-Lys-Leu (<u>SEQ ID NO:3</u>)	Cholesterol
2	Retinoic Acid	Gly-Thr-Thr-Arg-Leu-Thr-Arg-Lys-Arg-Gly-Leu-Lys-Leu- (<u>SEQ ID NO:4</u>)	-COOH

TABLE 1-continued

Peptide	N-terminal	Sequence	C-terminal
3	Retinoic Acid	Tyr-Lys-Leu-Glu-Gly- Thr-Thr-Arg-Leu-Thr- Arg-Lys-Arg-Gly-Leu- Lys-Leu-Ala-Thr-Ala- Leu-Ser- <u>Tyr-Lys-Leu-Glu-Gly-</u> <u>Thr-Thr-Arg-Leu-Thr-</u> <u>Arg-Lys-Arg-Gly-Leu-</u> <u>Lys-Leu-Ala-Thr-Ala-</u> <u>Leu-Ser- (SEQ ID NO:5)</u>	Cholesterol
4	Pyrene Butyric Acid	Lys-Leu-Glu-Gly-Thr- Thr-Arg-Leu-Thr-Arg- Lys-Arg-Gly-Leu-Lys- Leu-Ala-Thr-Ala-Leu- Ser-Leu-Phe-Leu-Phe- <u>(SEQ ID NO:6)</u>	Cholesterol